Citigroup Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX) had its price target decreased by research analysts at Citigroup from $7.00 to $6.25 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target would suggest a potential upside of 37.36% from the stock’s current price.

Several other equities research analysts also recently weighed in on the stock. Barclays decreased their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Mizuho began coverage on shares of GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target on the stock. KeyCorp dropped their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Morgan Stanley dropped their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.38.

GoodRx Trading Up 6.3 %

GDRX opened at $4.55 on Friday. GoodRx has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a market cap of $1.73 billion, a P/E ratio of -151.67, a price-to-earnings-growth ratio of 3.43 and a beta of 1.27. The company has a fifty day moving average price of $4.72 and a two-hundred day moving average price of $6.56.

Institutional Investors Weigh In On GoodRx

Several institutional investors and hedge funds have recently modified their holdings of the stock. American Century Companies Inc. bought a new position in shares of GoodRx in the 2nd quarter worth about $18,183,000. Cornercap Investment Counsel Inc. increased its stake in shares of GoodRx by 1.7% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock worth $587,000 after acquiring an additional 1,266 shares in the last quarter. Plato Investment Management Ltd bought a new position in shares of GoodRx in the 2nd quarter worth about $43,000. XTX Topco Ltd increased its stake in shares of GoodRx by 42.4% in the 2nd quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after acquiring an additional 8,801 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in shares of GoodRx by 5.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock worth $1,296,000 after acquiring an additional 9,200 shares in the last quarter. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.